"Congratulations are due to the many former and current WRAIR investigators who have helped to develop and test this vaccine over the last 20 years," said Col.
Results of the RTS,S phase III vaccine trial being conducted in
The phase III study involved more than 15,000 children across 11 sites in seven African countries. The results demonstrated a 46 percent reduction in clinical malaria episodes among infants and children vaccinated at five to 17 months of age, and 27 percent among infants vaccinated at six to 12 weeks.
According to the
Malaria is a mosquito-borne parasitic disease that kills hundreds of thousands of people each year. Although initial results indicate positive outcomes over the short term, results over the long term suggest the effectiveness of the vaccine decreases over time. Ongoing research will explore whether a booster dose can increase protection over the long term (after 18 months) as well as other tools, such as the use of bed nets, to reduce risk.
The successful trials give hope that a malaria vaccine will be available by 2015, the same year in which
USAMRU-K is located in
For additional information, please visit:
USAMRU Kenya: http://www.usamrukenya.org/
USAMRU-K DEID: http://usamrukenya-deid.org/
Malaria Vaccine Initiative (MVI) Path: http://www.malariavaccine.org/about-overview.php
Army Medicine: http://armymedicine.mil/Pages/Home.aspx
Most Popular Stories
- Bipartisan Budget Deal Gets Key Support in House
- Bitcoin Clones Lurch Onto Financial Scene
- Clinton to Keynote Annual Simmons Leadership Conference
- TFA Recruiting DACA Recipients
- Scotch Whisky Sales Raise Distillers' Spirits
- Holiday Shopping Off to a Slow Start This Season
- Fake Deaf Interpreter Was Hallucinating, Has Schizophrenia
- Tea Party Glum in Face of Bipartisan Budget Deal
- Budget Deal Will Cut 220,000 Californians Out of Jobless Benefits
- Health Coverage Disparities Emerge Among States